#China #Shanghai #Inc. #financial results #111 #healthcare platform

111, Inc. Reports First Quarter 2025 Financial Results

On June 19, 2025, 111, Inc. (NASDAQ: YI), a prominent healthcare platform based in China, revealed its unaudited financial results for Q1 2025, emphasizing resilience amid a tough economic backdrop. The company's net revenues remained steady at approximately RMB 3.5 billion (around US$ 486.3 million), marking only a slight increase of 0.02% compared to the same period last year.

Key highlights from the financial report include:

• - Operating Expenses Reduction: Total operating expenses saw a 4.8% year-over-year decline, amounting to RMB 195.0 million (US$ 26.9 million). This reduction contributed to a decrease in operating expenses as a percentage of revenues, down from 5.8% to 5.5%.
• - Operational Profitability: While the income from operations dipped to RMB 0.1 million (US$ 0.02 million) from RMB 3.7 million, the net cash from operating activities remained positive at RMB 112.6 million (US$ 15.5 million).
• - Non-GAAP Metrics: Non-GAAP income from operations stood at RMB 4.3 million (US$ 0.6 million), below the RMB 8.9 million reported last year, indicating a focus on the company's operational performance excluding share-based compensations.

Mr. Junling Liu, the Co-Founder and CEO, emphasized the company's strategy to maintain stability in the face of external economic pressures. “Despite a challenging macroeconomic environment, we managed to uphold profitability and operating cash flows through diligent operational management,” he stated during the earnings call.

Furthermore, Liu pointed out the strategic focus on enhancing operational efficiency, highlighting significant reductions in both selling & marketing and technology expenses, which closely reflect the company’s commitment to prudent cost management.

Looking ahead, the company remains dedicated to leveraging technological advancements to bolster the healthcare supply chain. Liu noted plans for continued investment in artificial intelligence (AI) and digital solutions aimed at deepening customer engagement and refining the shopping experience for partners.

Financial health was again illustrated with the company holding cash and equivalents totaling RMB 556.8 million (around US$ 76.7 million) by March 31, 2025, up from RMB 518.3 million at the end of 2024.

111, Inc. continues to explore opportunities for growth in an evolving market landscape, utilizing its leading digital platform to enhance access to healthcare products and services. The ongoing commitment to operational efficiency and innovative solution provision positions the company favorably in the fast-paced healthcare sector.

As 111, Inc. navigates the future, stakeholders and investors watch closely to see how these strategies unfold and further shape the company's trajectory in the healthcare industry. With the foundation laid by strong financials in Q1 2025, the potential for long-term growth remains on the horizon.